These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
302 related articles for article (PubMed ID: 25262914)
1. Efficient in vitro gene therapy with PEG siRNA lipid nanocapsules for passive targeting strategy in melanoma. Resnier P; LeQuinio P; Lautram N; André E; Gaillard C; Bastiat G; Benoit JP; Passirani C Biotechnol J; 2014 Nov; 9(11):1389-401. PubMed ID: 25262914 [TBL] [Abstract][Full Text] [Related]
2. Efficient ferrocifen anticancer drug and Bcl-2 gene therapy using lipid nanocapsules on human melanoma xenograft in mouse. Resnier P; Galopin N; Sibiril Y; Clavreul A; Cayon J; Briganti A; Legras P; Vessières A; Montier T; Jaouen G; Benoit JP; Passirani C Pharmacol Res; 2017 Dec; 126():54-65. PubMed ID: 28159700 [TBL] [Abstract][Full Text] [Related]
3. EGFR siRNA lipid nanocapsules efficiently transfect glioma cells in vitro. Resnier P; David S; Lautram N; Delcroix GJ; Clavreul A; Benoit JP; Passirani C Int J Pharm; 2013 Oct; 454(2):748-55. PubMed ID: 23583841 [TBL] [Abstract][Full Text] [Related]
4. siRNA LNCs--a novel platform of lipid nanocapsules for systemic siRNA administration. David S; Resnier P; Guillot A; Pitard B; Benoit JP; Passirani C Eur J Pharm Biopharm; 2012 Jun; 81(2):448-52. PubMed ID: 22381204 [TBL] [Abstract][Full Text] [Related]
5. Tumor transfection after systemic injection of DNA lipid nanocapsules. Morille M; Passirani C; Dufort S; Bastiat G; Pitard B; Coll JL; Benoit JP Biomaterials; 2011 Mar; 32(9):2327-33. PubMed ID: 21185595 [TBL] [Abstract][Full Text] [Related]
6. Characterization and comparison of two novel nanosystems associated with siRNA for cellular therapy. André EM; Pensado A; Resnier P; Braz L; Rosa da Costa AM; Passirani C; Sanchez A; Montero-Menei CN Int J Pharm; 2016 Jan; 497(1-2):255-67. PubMed ID: 26617318 [TBL] [Abstract][Full Text] [Related]
7. PEGylated siRNA lipoplexes for silencing of BLIMP-1 in Primary Effusion Lymphoma: In vitro evidences of antitumoral activity. Belletti D; Tosi G; Forni F; Lagreca I; Barozzi P; Pederzoli F; Vandelli MA; Riva G; Luppi M; Ruozi B Eur J Pharm Biopharm; 2016 Feb; 99():7-17. PubMed ID: 26625717 [TBL] [Abstract][Full Text] [Related]
8. Development and characterization of siRNA lipoplexes: Effect of different lipids, in vitro evaluation in cancerous cell lines and in vivo toxicity study. Khatri N; Baradia D; Vhora I; Rathi M; Misra A AAPS PharmSciTech; 2014 Dec; 15(6):1630-43. PubMed ID: 25145330 [TBL] [Abstract][Full Text] [Related]
9. Enhanced siRNA delivery using cationic liposomes with new polyarginine-conjugated PEG-lipid. Kim HK; Davaa E; Myung CS; Park JS Int J Pharm; 2010 Jun; 392(1-2):141-7. PubMed ID: 20347025 [TBL] [Abstract][Full Text] [Related]
10. Galactosylated DNA lipid nanocapsules for efficient hepatocyte targeting. Morille M; Passirani C; Letrou-Bonneval E; Benoit JP; Pitard B Int J Pharm; 2009 Sep; 379(2):293-300. PubMed ID: 19505548 [TBL] [Abstract][Full Text] [Related]
11. Lipid-based nanoparticles for siRNA delivery in cancer therapy: paradigms and challenges. Gomes-da-Silva LC; Fonseca NA; Moura V; Pedroso de Lima MC; Simões S; Moreira JN Acc Chem Res; 2012 Jul; 45(7):1163-71. PubMed ID: 22568781 [TBL] [Abstract][Full Text] [Related]
12. Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting. Morille M; Montier T; Legras P; Carmoy N; Brodin P; Pitard B; Benoît JP; Passirani C Biomaterials; 2010 Jan; 31(2):321-9. PubMed ID: 19800113 [TBL] [Abstract][Full Text] [Related]
13. Small interfering RNA delivery into the liver by cationic cholesterol derivative-based liposomes. Hattori Y; Machida Y; Honda M; Takeuchi N; Yoshiike Y; Ohno H; Onishi H J Liposome Res; 2017 Dec; 27(4):264-273. PubMed ID: 27345333 [TBL] [Abstract][Full Text] [Related]
14. Development and characterization of immuno-nanocarriers targeting the cancer stem cell marker AC133. Bourseau-Guilmain E; Béjaud J; Griveau A; Lautram N; Hindré F; Weyland M; Benoit JP; Garcion E Int J Pharm; 2012 Feb; 423(1):93-101. PubMed ID: 21683129 [TBL] [Abstract][Full Text] [Related]
15. Model Affitin and PEG modifications onto siRNA lipid nanocapsules: cell uptake and Resnier P; Lepeltier E; Emina AL; Galopin N; Bejaud J; David S; Ballet C; Benvegnu T; Pecorari F; Chourpa I; Benoit JP; Passirani C RSC Adv; 2019 Aug; 9(47):27264-27278. PubMed ID: 35529231 [TBL] [Abstract][Full Text] [Related]
16. VCAM-1 specific PEGylated SAINT-based lipoplexes deliver siRNA to activated endothelium in vivo but do not attenuate target gene expression. Leus NG; Morselt HW; Zwiers PJ; Kowalski PS; Ruiters MH; Molema G; Kamps JA Int J Pharm; 2014 Jul; 469(1):121-31. PubMed ID: 24746643 [TBL] [Abstract][Full Text] [Related]
17. A Copper-Mediated Disulfiram-Loaded pH-Triggered PEG-Shedding TAT Peptide-Modified Lipid Nanocapsules for Use in Tumor Therapy. Zhang L; Tian B; Li Y; Lei T; Meng J; Yang L; Zhang Y; Chen F; Zhang H; Xu H; Zhang Y; Tang X ACS Appl Mater Interfaces; 2015 Nov; 7(45):25147-61. PubMed ID: 26501354 [TBL] [Abstract][Full Text] [Related]
18. Core-shell type lipid/rPAA-Chol polymer hybrid nanoparticles for in vivo siRNA delivery. Gao LY; Liu XY; Chen CJ; Wang JC; Feng Q; Yu MZ; Ma XF; Pei XW; Niu YJ; Qiu C; Pang WH; Zhang Q Biomaterials; 2014 Feb; 35(6):2066-78. PubMed ID: 24315577 [TBL] [Abstract][Full Text] [Related]
19. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy. Li TS; Yawata T; Honke K Eur J Pharm Sci; 2014 Feb; 52():48-61. PubMed ID: 24178005 [TBL] [Abstract][Full Text] [Related]
20. PEGylation of lipoplexes: The right balance between cytotoxicity and siRNA effectiveness. Lechanteur A; Furst T; Evrard B; Delvenne P; Hubert P; Piel G Eur J Pharm Sci; 2016 Oct; 93():493-503. PubMed ID: 27593989 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]